Table 2.
Patient characteristics at study enrolment
| SoC AC patients (n = 1173) | Intervention AC patients (n = 977) | Total (n = 2150) | |
|---|---|---|---|
| Number of ACs | 48 | 40 | 98 |
| Community ACs (vs. facility based ACs), n (%) | 567 (48.3%) | 434 (44.4%) | 1001 (46.6%) |
| Male, n (%) | 278 (23.7%) | 213 (21.8%) | 491 (22.8%) |
| Time on ART | |||
| Median time on ART, years (IQR) | 7.1 (4.5 to 10.5) | 7.4 (5.0 to 10.0) | 7.3 (4.7 to 10.2) |
| On ART <3 years, n (%) | 120 (10.2%) | 93 (9.5%) | 213 (9.9%) |
| Era of ART initiation (by CD4 count eligibility criteria), n (%) | |||
| <200 (before August 2011) | 672 (57.3%) | 611 (62.5%) | 1283 (59.7%) |
| <350 (Aug 2011 to 31 Dec 2014) | 398 (33.9%) | 280 (28.7%) | 678 (31.5%) |
| <500 (1 Jan 2015 to 31 Aug 2016) | 99 (8.4%) | 84 (8.6%) | 183 (8.5%) |
| All eligible (After 1 Sept 2016) | 4 (0.3%) | 1 (0.1%) | 5 (0.2%) |
| Age, n(%) | |||
| 18 to 34 years | 221 (18.8%) | 172 (17.6%) | 393 (18.3%) |
| 35 to 49 years | 759 (64.7%) | 646 (66.1%) | 1405 (65.3%) |
| 50 + years | 193 (16.5%) | 159 (16.3%) | 352 (16.4%) |
| Median age, years (IQR) | 41.4 (36.2 to 47.1) | 41.5 (36.6 to 47.3) | 41.4 (36.5 to 47.2) |
| On fixed dose regimen a , n (%) (TDF/FTC/EFV) | 1027 (87.6%) | 841 (86.1%) | 1868 (86.9%) |
| Baseline VL (0 to 18 months before first study visit), n (%) | |||
| Suppressed b | 1120 (95.5%) | 925 (94.7%) | 2045 (95.1%) |
| Unsuppressed | 19 (1.6%) | 18 (1.8%) | 37 (1.7%) |
| Incomplete | 34 (2.9%) | 34 (3.5%) | 68 (3.2%) |
AC, adherence club; ART, antiretroviral therapy; IQR, interquartile range; SoC, standard of care; VL, viral load.
a
Fixed dose regimen was tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) (TDF/FTC/EFV)
b
Suppressed was defined as having a documented viral load below 400 copies/mL in the past 18 months.